MeVis Medical Solutions AG

Business and Financial Review • Mar 6, 2009

News Details

Corporate | 6 March 2009 16:56

MeVis Medical Solutions joint venture MeVis BreastCare supplying diagnostic software for use with the world’s first multi-use ultrasound breast volume scanner developed by Siemens:

MeVis Medical Solutions AG / Alliance/Product Launch

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

MeVis Group highlighting its international leadership in image-based mamma
diagnostics with diagnostic software for volume images

* The software for the new Acuson S2000 automated breast volume scanner
(ABVS) developed by joint venture partner Siemens offers numerous
intelligent clinical diagnostic functions

* Considerable potential for use in early detection of breast cancer thanks
to user-independent standardized imaging and volume scans

* Enhanced workflow efficiency opening up possibilities for use by
physicians in private practice

Bremen, March 6, 2009 - MeVis Medical Solutions AG (ISIN: DE000A0LBFE4), a
specialist in software for image-based medicine, has today announced that
the diagnostic software, which was developed by MeVis BreastCare, a joint
venture which it operates with Siemens AG, will be presented by Siemens
together with its new automated breast volume scanner Acuson S2000 ABVS at
the European Conference of Radiologists (ECR) in Vienna.

The new Acuson S2000 ABVS automated breast volume scanner performs
automatic, user-independent and swift full-field ultrasonic breast scans.
The volume images now provide medical practitioners with information of an
additional plane previously not available with conventional ultrasound.
This so called coronal view of the breast (from the nipple to the breast
wall) additionally offers an important instrument in planning surgery.

Recent scientific research has shown that ultrasound provides a medically
extremely valuable supplement to digital mammography particularly in the
case of younger patients who typically have dense breast tissue, especially
if they are at risk. Using modern volume-based ultrasound, it is also
possible to identify lesions which otherwise go undetected in
two-dimensional imaging modalities. Looking forward, the combined
deployment of digital mammography and ultrasound will result in a further
substantial increase in detection rates for non-palpable invasive breast
cancer.

'I am convinced that automated ultrasound volume imaging with the Acuson
S2000 ABVS can make a significant contribution to diagnostic confidence for
women with dense breast tissue or inconclusive mammography findings,' says
Klaus Hambüchen CEO of Ultrasound at Siemens Healthcare. Examinations
performed with the Acuson S2000 ABVS technique generally take less than 15
minutes. 'Time well spent if you consider the extended diagnostic
capabilities of ultrasound in dense breasts.'

'Detaching the imaging from the diagnostic process gives rise to entirely
new clinical workflow possibilities, resulting in considerable potential
for saving time and expense while enhancing diagnostic quality,' adds Dr.
Carl J.G. Evertsz, CEO of MeVis Medical Solutions AG and managing director
of the MeVis BreastCare joint venture with Siemens. 'In this way, the
medical practitioner can examine the images for several patients in a
concentrated work flow at any time after the data has been recorded. As a
result, the process offers considerable potential for use in the early
detection of breast cancer.'

The intelligent image suspension system implemented in the diagnostic
software permits, for example, the freely configurable automated
synchronization of image data, thus enabling earlier images of the same
patient to be compared swiftly and reliably. As well as this, the system
supports the semi-automated production of diagnostic reports including
BI-RADS. Developed by the American College of Radiology (ACR), the Breast
Imaging Reporting and Data System (BI-RADS) is used to classify the results
of mammography scans. If necessary, the lesions discovered can be grouped
together and stored using a standardized data format in clinical PACS
(Picture Archiving and Communication Systems), where they can be retrieved
at any time later on.

Clinical application testing has since been completed successfully in the
United States, Japan and Germany. 'Once final approval has been granted by
the responsible regulatory authorities, we expect this medically
significant software solution to start generating initial revenues in the
second quarter,' says Christian H. Seefeldt, CFO at MeVis Medical Solutions
AG. License income will be reported in the Digital Mammography segment in
the future.
06.03.2009 Financial News transmitted by DGAP

---

Language: English
Issuer: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, München, Düsseldorf, Stuttgart

End of News DGAP News-Service

---